Tebotelimab plus niraparib in previously treated locally advanced or metastatic solid tumors: A phase 1b dose escalation and expansion study
Tebotelimab plus niraparib preliminarily demonstrated a tolerated and manageable safety profile and limited antitumor activity in patients with previously treated solid tumors.
Authors
- Xinhong Wu (ORCID: https://orcid.org/0000-0002-7544-5544)
- Yu Zheng (ORCID: https://orcid.org/0000-0003-2639-3765)
- Yanxia Shi (ORCID: https://orcid.org/0000-0002-9658-0032)
- Lequn Bao
- Min Yan (ORCID: https://orcid.org/0000-0002-7823-2405)
- R. Xu (ORCID: https://orcid.org/0009-0004-7239-0914)
- Jianmei Hou (ORCID: https://orcid.org/0000-0002-9148-4121)
- Yunong Gao (ORCID: https://orcid.org/0000-0001-9926-0360)
- Miao‐Zhen Qiu (ORCID: https://orcid.org/0000-0002-4774-6235)
- Li Wang (ORCID: https://orcid.org/0000-0001-5691-9946)
- Huiping Li (ORCID: https://orcid.org/0000-0002-3331-647X)
- Jing Cheng (ORCID: https://orcid.org/0000-0002-6145-1003)
- Hui Luo (ORCID: https://orcid.org/0000-0001-6312-9299)
- Jufeng Wang (ORCID: https://orcid.org/0000-0002-5933-2152)
- Yi Zheng (ORCID: https://orcid.org/0000-0002-7066-2937)
- Ka On Lam
- Hongming Pan
- Xiaoa Zhen
- Wenzhao Hang
Institutions
- Union Hospital (HK)
- Sun Yat-sen University (CN)
- Peking University (CN)
- Queen Mary Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- Zhengzhou University (CN)
- Peking University Cancer Hospital (CN)
- Wuhan Union Hospital (CN)
- Shanghai Chengtou (China) (CN)
- MRC Biostatistics Unit (GB)
- Henan Cancer Hospital (CN)
- Sun Yat-sen University Cancer Center (CN)
- Hubei Cancer Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Huazhong University of Science and Technology (CN)
- Zhejiang University (CN)
- University of Hong Kong (HK)
Publication Details
- Journal
- Cancer
- Published
- 2025-05-30
- DOI
- https://doi.org/10.1002/cncr.35919
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05